← Back to Search

Local Anesthetic

Bupivacaine Hydrochloride for Labor Pain

Phase 4
Waitlist Available
Led By Lawrence Tsen, MD
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Parturient with no major co-morbidities
Singleton, vertex gestation at term (37-42 weeks)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 minutes
Awards & highlights

Study Summary

This study is evaluating whether a specific dose of a local anesthetic may help reduce pain for women during labor.

Eligible Conditions
  • Labor Pain
  • Pain relief

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Verbal Numerical Rating Score (0-10, with higher scores meaning more pain); goal with analgesia is < 3/10

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Dural Puncture Epidural TechniqueExperimental Treatment1 Intervention
Laboring women receiving the Dural Puncture Epidural (DPE) Technique with dose of Bupivacaine 0.25% diluted to 20 mL with isotonic sterile 0.9% saline. The first subject in the DPE group will receive an initial dose of bupivacaine 25 mg, with an endpoint being the achievement of an NRS < 3 at 30 min. Subsequent patients are administered bupivacaine doses determined by the response of the previous subject, as per the biased coin method. The subsequent up and down interval doses are bupivacaine 2.5 mg (1 mL) increments, with an anticipated dose range from 20 mg to 40 mg.
Group II: Epidural TechniqueActive Control1 Intervention
Laboring women receiving the Conventional Epidural Technique (EPL) with dose of Bupivacaine 0.25% diluted to 20 mL with isotonic sterile 0.9% saline. The first subject in the EPL group will receive an initial dose of bupivacaine 25 mg, with an endpoint being the achievement of an NRS < 3 at 30 min. Subsequent patients are administered bupivacaine doses determined by the response of the previous subject, as per the biased coin method. The subsequent up and down interval doses are bupivacaine 2.5 mg (1 mL) increments, with an anticipated dose range from 20 mg to 40 mg.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bupivacaine
FDA approved

Find a Location

Who is running the clinical trial?

Brigham and Women's HospitalLead Sponsor
1,600 Previous Clinical Trials
11,462,825 Total Patients Enrolled
3 Trials studying Labor Pain
360 Patients Enrolled for Labor Pain
Lawrence Tsen, MDPrincipal InvestigatorAssociate Professor in Anesthesiology, Harvard Medical School
1 Previous Clinical Trials
234 Total Patients Enrolled

Frequently Asked Questions

~24 spots leftby Mar 2025